An Innovative Phase I Clinical Study Demonstrates Inhibition of FLT3 Phosphorylation by SU11248 in Acute Myeloid Leukemia Patients

Anne Marie O'Farrell, James M Foran, Walter Fiedler, Hubert Serve, Ron L. Paquette, Maureen A. Cooper, Helene A. Yuen, Sharianne G. Louie, Heidi Kim, Susan Nicholas, Michael C. Heinrich, Wolfgang E. Berdel, Carlo Bello, Mark Jacobs, Paul Scigalla, William C. Manning, Stephen Kelsey, Julie M. Cherrington

Research output: Contribution to journalArticle

266 Citations (Scopus)

Abstract

Purpose: Obtaining direct and rapid proof of molecular activity in early clinical trials is critical for optimal clinical development of novel targeted therapies. SU11248 is an oral multitargeted kinase inhibitor with selectivity for fms-related tyrosine kinase 3/Flk2 (FLT3), platelet-derived growth factor receptor α/β, vascular endothelial growth factor receptor 1/2, and KIT receptor tyrosine kinases. FLT3 is a promising candidate for targeted therapy in acute myeloid leukemia (AML), because activating mutations occur in up to 30% of patients. We conducted an innovative single-dose clinical study with a primary objective to demonstrate inhibition of FLT3 phosphorylation by SU11248 in AML. Experimental Design: Twenty-nine AML patients each received a single dose of SU11248, escalated from 50 to 350 mg, in increments of 50 mg and cohorts of three to six patients. FLT3 phosphorylation and plasma pharmacokinetics were evaluated at seven time points over 48 h after SU11248 administration, and FLT3 genotype was determined. Study drug-related adverse events occurred in 31% of patients, mainly grade 1 or 2 diarrhea and nausea, at higher dose levels. Results: Inhibition of FLT3 phosphorylation was apparent in 50% of FLT3-wild-type (WT) patients and in 100% of FLT3-mutant patients. FLT3 internal tandem duplication (ITD) mutants showed increased sensitivity relative to FLT3-WT, consistent with preclinical predictions. The primary end point, strong inhibition of FLT3 phosphorylation in >50% patients, was reached in 200 mg and higher dose cohorts. Downstream signaling pathways were also inhibited; signal transducer and activator of transcription 5 (STAT5) was reduced primarily in internal tandem duplication patients and at late time points in FLT3-WT patients, whereas extracellular signal-regulated kinase (ERK) activity was reduced in the majority of patients, independent of FLT3 inhibition. Conclusions: This novel translational study bridges preclinical models to the patient setting and provides the first evidence of anti-FLT3 activity in patients. Proof of target inhibition accomplishes a crucial milestone in the development of novel oncology therapeutics.

Original languageEnglish (US)
Pages (from-to)5465-5476
Number of pages12
JournalClinical Cancer Research
Volume9
Issue number15
StatePublished - Nov 15 2003
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Phosphorylation
Clinical Studies
sunitinib
STAT5 Transcription Factor
Vascular Endothelial Growth Factor Receptor-1
Platelet-Derived Growth Factor Receptors
Vascular Endothelial Growth Factor Receptor-2
Extracellular Signal-Regulated MAP Kinases
Receptor Protein-Tyrosine Kinases
Drug-Related Side Effects and Adverse Reactions
Protein-Tyrosine Kinases
Nausea
Diarrhea
Research Design
Phosphotransferases
Therapeutics
Pharmacokinetics
Genotype
Clinical Trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

O'Farrell, A. M., Foran, J. M., Fiedler, W., Serve, H., Paquette, R. L., Cooper, M. A., ... Cherrington, J. M. (2003). An Innovative Phase I Clinical Study Demonstrates Inhibition of FLT3 Phosphorylation by SU11248 in Acute Myeloid Leukemia Patients. Clinical Cancer Research, 9(15), 5465-5476.

An Innovative Phase I Clinical Study Demonstrates Inhibition of FLT3 Phosphorylation by SU11248 in Acute Myeloid Leukemia Patients. / O'Farrell, Anne Marie; Foran, James M; Fiedler, Walter; Serve, Hubert; Paquette, Ron L.; Cooper, Maureen A.; Yuen, Helene A.; Louie, Sharianne G.; Kim, Heidi; Nicholas, Susan; Heinrich, Michael C.; Berdel, Wolfgang E.; Bello, Carlo; Jacobs, Mark; Scigalla, Paul; Manning, William C.; Kelsey, Stephen; Cherrington, Julie M.

In: Clinical Cancer Research, Vol. 9, No. 15, 15.11.2003, p. 5465-5476.

Research output: Contribution to journalArticle

O'Farrell, AM, Foran, JM, Fiedler, W, Serve, H, Paquette, RL, Cooper, MA, Yuen, HA, Louie, SG, Kim, H, Nicholas, S, Heinrich, MC, Berdel, WE, Bello, C, Jacobs, M, Scigalla, P, Manning, WC, Kelsey, S & Cherrington, JM 2003, 'An Innovative Phase I Clinical Study Demonstrates Inhibition of FLT3 Phosphorylation by SU11248 in Acute Myeloid Leukemia Patients', Clinical Cancer Research, vol. 9, no. 15, pp. 5465-5476.
O'Farrell, Anne Marie ; Foran, James M ; Fiedler, Walter ; Serve, Hubert ; Paquette, Ron L. ; Cooper, Maureen A. ; Yuen, Helene A. ; Louie, Sharianne G. ; Kim, Heidi ; Nicholas, Susan ; Heinrich, Michael C. ; Berdel, Wolfgang E. ; Bello, Carlo ; Jacobs, Mark ; Scigalla, Paul ; Manning, William C. ; Kelsey, Stephen ; Cherrington, Julie M. / An Innovative Phase I Clinical Study Demonstrates Inhibition of FLT3 Phosphorylation by SU11248 in Acute Myeloid Leukemia Patients. In: Clinical Cancer Research. 2003 ; Vol. 9, No. 15. pp. 5465-5476.
@article{f55b22c649d6486baa41ce8071da2662,
title = "An Innovative Phase I Clinical Study Demonstrates Inhibition of FLT3 Phosphorylation by SU11248 in Acute Myeloid Leukemia Patients",
abstract = "Purpose: Obtaining direct and rapid proof of molecular activity in early clinical trials is critical for optimal clinical development of novel targeted therapies. SU11248 is an oral multitargeted kinase inhibitor with selectivity for fms-related tyrosine kinase 3/Flk2 (FLT3), platelet-derived growth factor receptor α/β, vascular endothelial growth factor receptor 1/2, and KIT receptor tyrosine kinases. FLT3 is a promising candidate for targeted therapy in acute myeloid leukemia (AML), because activating mutations occur in up to 30{\%} of patients. We conducted an innovative single-dose clinical study with a primary objective to demonstrate inhibition of FLT3 phosphorylation by SU11248 in AML. Experimental Design: Twenty-nine AML patients each received a single dose of SU11248, escalated from 50 to 350 mg, in increments of 50 mg and cohorts of three to six patients. FLT3 phosphorylation and plasma pharmacokinetics were evaluated at seven time points over 48 h after SU11248 administration, and FLT3 genotype was determined. Study drug-related adverse events occurred in 31{\%} of patients, mainly grade 1 or 2 diarrhea and nausea, at higher dose levels. Results: Inhibition of FLT3 phosphorylation was apparent in 50{\%} of FLT3-wild-type (WT) patients and in 100{\%} of FLT3-mutant patients. FLT3 internal tandem duplication (ITD) mutants showed increased sensitivity relative to FLT3-WT, consistent with preclinical predictions. The primary end point, strong inhibition of FLT3 phosphorylation in >50{\%} patients, was reached in 200 mg and higher dose cohorts. Downstream signaling pathways were also inhibited; signal transducer and activator of transcription 5 (STAT5) was reduced primarily in internal tandem duplication patients and at late time points in FLT3-WT patients, whereas extracellular signal-regulated kinase (ERK) activity was reduced in the majority of patients, independent of FLT3 inhibition. Conclusions: This novel translational study bridges preclinical models to the patient setting and provides the first evidence of anti-FLT3 activity in patients. Proof of target inhibition accomplishes a crucial milestone in the development of novel oncology therapeutics.",
author = "O'Farrell, {Anne Marie} and Foran, {James M} and Walter Fiedler and Hubert Serve and Paquette, {Ron L.} and Cooper, {Maureen A.} and Yuen, {Helene A.} and Louie, {Sharianne G.} and Heidi Kim and Susan Nicholas and Heinrich, {Michael C.} and Berdel, {Wolfgang E.} and Carlo Bello and Mark Jacobs and Paul Scigalla and Manning, {William C.} and Stephen Kelsey and Cherrington, {Julie M.}",
year = "2003",
month = "11",
day = "15",
language = "English (US)",
volume = "9",
pages = "5465--5476",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - An Innovative Phase I Clinical Study Demonstrates Inhibition of FLT3 Phosphorylation by SU11248 in Acute Myeloid Leukemia Patients

AU - O'Farrell, Anne Marie

AU - Foran, James M

AU - Fiedler, Walter

AU - Serve, Hubert

AU - Paquette, Ron L.

AU - Cooper, Maureen A.

AU - Yuen, Helene A.

AU - Louie, Sharianne G.

AU - Kim, Heidi

AU - Nicholas, Susan

AU - Heinrich, Michael C.

AU - Berdel, Wolfgang E.

AU - Bello, Carlo

AU - Jacobs, Mark

AU - Scigalla, Paul

AU - Manning, William C.

AU - Kelsey, Stephen

AU - Cherrington, Julie M.

PY - 2003/11/15

Y1 - 2003/11/15

N2 - Purpose: Obtaining direct and rapid proof of molecular activity in early clinical trials is critical for optimal clinical development of novel targeted therapies. SU11248 is an oral multitargeted kinase inhibitor with selectivity for fms-related tyrosine kinase 3/Flk2 (FLT3), platelet-derived growth factor receptor α/β, vascular endothelial growth factor receptor 1/2, and KIT receptor tyrosine kinases. FLT3 is a promising candidate for targeted therapy in acute myeloid leukemia (AML), because activating mutations occur in up to 30% of patients. We conducted an innovative single-dose clinical study with a primary objective to demonstrate inhibition of FLT3 phosphorylation by SU11248 in AML. Experimental Design: Twenty-nine AML patients each received a single dose of SU11248, escalated from 50 to 350 mg, in increments of 50 mg and cohorts of three to six patients. FLT3 phosphorylation and plasma pharmacokinetics were evaluated at seven time points over 48 h after SU11248 administration, and FLT3 genotype was determined. Study drug-related adverse events occurred in 31% of patients, mainly grade 1 or 2 diarrhea and nausea, at higher dose levels. Results: Inhibition of FLT3 phosphorylation was apparent in 50% of FLT3-wild-type (WT) patients and in 100% of FLT3-mutant patients. FLT3 internal tandem duplication (ITD) mutants showed increased sensitivity relative to FLT3-WT, consistent with preclinical predictions. The primary end point, strong inhibition of FLT3 phosphorylation in >50% patients, was reached in 200 mg and higher dose cohorts. Downstream signaling pathways were also inhibited; signal transducer and activator of transcription 5 (STAT5) was reduced primarily in internal tandem duplication patients and at late time points in FLT3-WT patients, whereas extracellular signal-regulated kinase (ERK) activity was reduced in the majority of patients, independent of FLT3 inhibition. Conclusions: This novel translational study bridges preclinical models to the patient setting and provides the first evidence of anti-FLT3 activity in patients. Proof of target inhibition accomplishes a crucial milestone in the development of novel oncology therapeutics.

AB - Purpose: Obtaining direct and rapid proof of molecular activity in early clinical trials is critical for optimal clinical development of novel targeted therapies. SU11248 is an oral multitargeted kinase inhibitor with selectivity for fms-related tyrosine kinase 3/Flk2 (FLT3), platelet-derived growth factor receptor α/β, vascular endothelial growth factor receptor 1/2, and KIT receptor tyrosine kinases. FLT3 is a promising candidate for targeted therapy in acute myeloid leukemia (AML), because activating mutations occur in up to 30% of patients. We conducted an innovative single-dose clinical study with a primary objective to demonstrate inhibition of FLT3 phosphorylation by SU11248 in AML. Experimental Design: Twenty-nine AML patients each received a single dose of SU11248, escalated from 50 to 350 mg, in increments of 50 mg and cohorts of three to six patients. FLT3 phosphorylation and plasma pharmacokinetics were evaluated at seven time points over 48 h after SU11248 administration, and FLT3 genotype was determined. Study drug-related adverse events occurred in 31% of patients, mainly grade 1 or 2 diarrhea and nausea, at higher dose levels. Results: Inhibition of FLT3 phosphorylation was apparent in 50% of FLT3-wild-type (WT) patients and in 100% of FLT3-mutant patients. FLT3 internal tandem duplication (ITD) mutants showed increased sensitivity relative to FLT3-WT, consistent with preclinical predictions. The primary end point, strong inhibition of FLT3 phosphorylation in >50% patients, was reached in 200 mg and higher dose cohorts. Downstream signaling pathways were also inhibited; signal transducer and activator of transcription 5 (STAT5) was reduced primarily in internal tandem duplication patients and at late time points in FLT3-WT patients, whereas extracellular signal-regulated kinase (ERK) activity was reduced in the majority of patients, independent of FLT3 inhibition. Conclusions: This novel translational study bridges preclinical models to the patient setting and provides the first evidence of anti-FLT3 activity in patients. Proof of target inhibition accomplishes a crucial milestone in the development of novel oncology therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=0345359585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345359585&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 5465

EP - 5476

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 15

ER -